Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney, and thyroid cancers using its investigational therapy LP-184 (zirdafulven). The allowed claims focus on a three-gene biomarker signature involving elevated expression of PTGR1, PTPN14, and ASPH to identify patients who may benefit from treatment.
The company's RADR artificial intelligence platform was instrumental in identifying the biomarker signature, supporting a precision medicine approach for LP-184. In its Phase 1a trial, Lantern reported a 45% disease control rate among patients treated at or above the effective therapeutic dose. The company plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while continuing to expand its intellectual property portfolio.
This patent allowance is significant because it strengthens Lantern's position in precision oncology, potentially enabling more targeted and effective treatments for difficult-to-treat cancers. By using a biomarker signature to select patients, the therapy could improve outcomes and reduce unnecessary side effects. For patients with ovarian, liver, kidney, and thyroid cancers, this approach offers hope for more personalized treatment options. The advancement of LP-184 into later-stage trials could also impact the oncology drug development landscape, demonstrating the value of AI-driven biomarker discovery.
Lantern Pharma is a clinical-stage precision oncology company leveraging its proprietary RADR platform to transform cancer therapy development. The company's pipeline also includes LP-284 for hematologic and solid tumors and LP-300 for lung adenocarcinoma, with LP-184 also being developed for pediatric CNS cancers through its subsidiary Starlight Therapeutics. Additionally, Lantern's withZeta.ai platform is commercially available as a subscription-based research tool. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
For more information, visit the company's newsroom at https://ibn.fm/LTRN.
